Høhloch, Karin

[["dc.bibliographiccitation.firstpage","181"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","eJHaem"],["dc.bibliographiccitation.lastpage","187"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Høhloch, Karin"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Buske, Christian"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Poeschel, Viola"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Altmann, Bettina"],["dc.date.accessioned","2020-12-11T11:48:55Z"],["dc.date.accessioned","2021-10-27T13:22:25Z"],["dc.date.available","2020-12-11T11:48:55Z"],["dc.date.available","2021-10-27T13:22:25Z"],["dc.date.issued","2020"],["dc.description.abstract","Serum albumin a well‐known risk factor predicting outcome in many solid tumors. We explore the role of low serum albumin (≤3.5 g/dL) as an independent risk factor in elderly patients with aggressive B‐cell lymphoma. Outcome of 429 patients treated with R‐CHOP‐14 in the RICOVER‐60 trial and available serum albumin were analyzed in this retrospective study. Of the 429 patients in the RICOVER‐60 trial, 137 (32%) had low and 292 (68%) had normal serum albumin levels (>3.5 g/dL). In the low albumin group, patients had significantly higher International Prognostic Index (IPI), bulky disease, extralymphatic involvement, and B‐symptoms. Event‐free survival (EFS) (P < .001), progression‐free survival (PFS) (P < .001), and overall survival (OS) (P < .001) were significantly inferior for patients with low compared to those with normal serum albumin. Multivariate analysis adjusted for IPI shows following Hazard ratios (HR) for low serum albumin: EFS (HR = 1.5; 95% confidance interval [CI] [1.1; 2.1], P = .009), PFS (HR = 1.7; 95% CI [1.2; 2.4], P = .001) and OS (HR = 1.6; 95% CI [1.1; 2.3], P = .006). Results were confirmed in 185 patients from the DENSE‐R‐CHOP‐14 and SMARTE‐R‐CHOP‐14 trials. In conclusion, low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma treated with R‐CHOP."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1002/jha2.61"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17695"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92093"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","2688-6146"],["dc.relation.issn","2688-6146"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Leukemia"],["dc.bibliographiccitation.lastpage","161"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Buske, Christian"],["dc.contributor.author","Hoster, E."],["dc.contributor.author","Dreyling, M."],["dc.contributor.author","Eimermacher, Hartmut"],["dc.contributor.author","Wandt, Hannes"],["dc.contributor.author","Metzner, Bernd"],["dc.contributor.author","Fuchs, Rene"],["dc.contributor.author","Bittenbring, Joerg"],["dc.contributor.author","Woermann, Bernhard"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Hess, Georg"],["dc.contributor.author","Ludwig, W-D"],["dc.contributor.author","Schimke, J."],["dc.contributor.author","Schmitz, S."],["dc.contributor.author","Kneba, Michael"],["dc.contributor.author","Reiser, M."],["dc.contributor.author","Graeven, Ullrich"],["dc.contributor.author","Klapper, Wolfram"],["dc.contributor.author","Unterhalt, Michael"],["dc.contributor.author","Hiddemann, Wolfgang"],["dc.date.accessioned","2018-11-07T08:35:03Z"],["dc.date.available","2018-11-07T08:35:03Z"],["dc.date.issued","2009"],["dc.description.abstract","Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n = 34) or CHOP (n = 30). R-CHOP resulted in significantly higher overall response (OR) rate (94 vs 67%, P = 0.0085) in the LPL patients and in the WM subgroup (91 vs 60%, P = 0.0188). With a median observation time of 42 months, R-CHOP induced a significantly longer time to treatment failure (TTF) with a median of 63 months for R-CHOP vs 22 months in the CHOP arm in the LPL patients (P = 0.0033) and in the WM subgroup (P = 0.0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM."],["dc.identifier.doi","10.1038/leu.2008.261"],["dc.identifier.isi","000262470700018"],["dc.identifier.pmid","18818699"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17967"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0887-6924"],["dc.title","The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]